venetoclax + azacitidine

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myelodysplastic Syndromes (MDS)

Conditions

Myelodysplastic Syndromes (MDS)

Trial Timeline

Mar 7, 2017 → Apr 5, 2023

NCT ID

NCT02966782

About venetoclax + azacitidine

venetoclax + azacitidine is a phase 1 stage product being developed by AbbVie for Myelodysplastic Syndromes (MDS). The current trial status is completed. This product is registered under clinical trial identifier NCT02966782. Target conditions include Myelodysplastic Syndromes (MDS).

What happened to similar drugs?

7 of 19 similar drugs in Myelodysplastic Syndromes (MDS) were approved

Approved (7) Terminated (7) Active (7)

✅decitabine + azacitidineEisaiApproved

✅DeferasiroxNovartisApproved

✅ICL670/DeferasiroxNovartisApproved

✅deferasiroxNovartisApproved

✅DeferasiroxNovartisApproved

✅Epoetin betaRocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05144243	Approved	Active	Jan 6, 2022	Mar 1, 2026	Acute Myeloid Leukemia (AML)
NCT04161885	Phase 3	Terminated	Feb 26, 2020	Sep 23, 2025	Acute Myeloid Leukemia (AML)
NCT02966782	Phase 1	Completed	Mar 7, 2017	Apr 5, 2023	Myelodysplastic Syndromes (MDS)

Competing Products

20 competing products in Myelodysplastic Syndromes (MDS)

See all competitors

Product	Company	Stage	Hype Score
NEX-18a injection + Azacitidine Injection	Nanexa AB	Phase 1	23
JSP191	Jasper Therapeutics	Phase 1	11
Humanized anti-CD117 Monoclonal Antibody (JSP191)	Jasper Therapeutics	Phase 1	15
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II	GT Biopharma	Phase 1/2	14
Erlotinib Hydrochloride	Astellas Pharma	Phase 2	35
Decitabine + Decitabine + Decitabine	Eisai	Phase 2	35
Decitabine + Valproic Acid	Eisai	Phase 2	35
decitabine + decitabine	Eisai	Phase 2	35
decitabine + azacitidine	Eisai	Approved	35
Decitabine	Eisai	Phase 2	27
decitabine + decitabine + decitabine + decitabine	Eisai	Phase 1	29
Decitabine, Arsenic Trioxide and Ascorbic Acid	Eisai	Phase 2	35
Subcutaneous Decitabine	Eisai	Phase 1	21
Decitabine	Eisai	Phase 2	35
Galunisertib + Placebo	Eli Lilly	Phase 2/3	38
DSP-7888	Sumitomo Pharma	Phase 1/2	32
TP-0184	Sumitomo Pharma	Phase 1/2	24
Decitabine	Johnson & Johnson	Phase 2	35
Epoetin alfa	Johnson & Johnson	Phase 2	27
ZARNESTRA, tipifarnib, R115777	Johnson & Johnson	Phase 2	35